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ABSTRACT 23 
TIN2 is central to the shelterin complex, linking the telomeric proteins TRF1 and 24 
TRF2 with TPP1/POT1. Mutations in TINF2, which encodes TIN2, that are found in 25 
dyskeratosis congenita (DC) result in very short telomeres and cluster in a region 26 
shared by the two TIN2 isoforms, TIN2S (short) and TIN2L (long). Here we show that 27 
TIN2L, but not TIN2S, is phosphorylated. TRF2 interacts more with TIN2L than TIN2S, 28 
and both the DC-cluster and phosphorylation promote this enhanced interaction. The 29 
binding of TIN2L, but not TIN2S, is affected by TRF2-F120, which is also required for 30 
TRF2's interaction with end processing factors such as Apollo. Conversely, TRF1 31 
interacts more with TIN2S than with TIN2L. A DC-associated mutation further reduces 32 
TIN2L-TRF1, but not TIN2S-TRF1, interaction. Cells overexpressing TIN2L or 33 
phosphomimetic-TIN2L are permissive to telomere elongation, whereas cells 34 
overexpressing TIN2S or phosphodead-TIN2L are not. Telomere lengths are 35 
unchanged in cell lines in which TIN2L expression has been eliminated by 36 
CRISPR/Cas9-mediated mutation. These results indicate that TIN2 isoforms are 37 
biochemically and functionally distinguishable, and that shelterin composition could be 38 
fundamentally altered in patients with TINF2 mutations. 39 
  40 
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INTRODUCTION 41 
The stability of the natural ends of linear chromosomes can be compromised by 42 
two major processes: progressive shortening with each round of DNA replication, due to 43 
the so-called end-replication problem, and misrecognition of the ends as DNA double 44 
strand breaks (DSBs), leading to activation of the DNA damage response (DDR) and 45 
DSB repair pathways.  In most eukaryotes, telomeres, the specialized nucleoprotein 46 
structures at the chromosome termini, enforce chromosomal end stability through the 47 
activity of telomere-associated factors that inhibit activation of the DDR. These 48 
telomere-associated factors also play a crucial role in regulating the access and activity 49 
of the reverse transcriptase telomerase, which replenishes terminal telomeric repeats. 50 
In vertebrates, the shelterin complex, comprised of the TRF1, TRF2, RAP1, TIN2, TPP1 51 
and POT1 proteins, plays an integral role in both of these functions (1-6). 52 
 TIN2 is a central component of shelterin, linking the double stranded telomeric 53 
binding proteins, TRF1 and TRF2, to the single stranded telomeric binding protein 54 
POT1 via its interaction with TPP1 (7). Additionally, TIN2 interacts with the cohesin 55 
subunit SA1 (8). Whereas murine cells express a single TIN2 isoform, which is 56 
important for the protection of telomeres from DNA damage signaling and fusions via 57 
classical- and alternative-non-homologous end joining pathways (9), both a short 58 
(TIN2S) and long (TIN2L) isoform of TIN2 are expressed in human cell lines (10) (Fig. 59 
1A). TIN2L contains all 354 amino acids (aa) present in the shorter isoform along with 60 
an additional 97 aa at the C terminus via alternative splicing. Detailed interaction studies 61 
published to date have focused on residues shared between TIN2S and TIN2L or the 62 
full length TIN2S isoform. For example, of the TIN2 crystal structures that have been 63 
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reported, the first set consists of a small central peptide spanning aa 256-276, which 64 
includes a TRF homology (TRFH) domain binding motif (TBM), in complex with the 65 
TRF1- or TRF2- TRFH domains (9). The second set consists of the N terminal domain 66 
of TIN2 (aa 2-202), which structurally resembles a TRFH domain, in a ternary complex 67 
with TPP1- and TRF2-TBMs (11). While the TIN2-TBM interacts with TRF2 with a much 68 
lower affinity than the TIN2-TRFH domain does, in vivo studies with TIN2S have 69 
demonstrated that residues within the TIN2-TBM can mediate a weak interaction with 70 
TRF2 when the interaction between the TIN2-TRFH and TRF2 is disrupted. 71 
Interestingly, in contrast to its interaction with the TRF2-TRFH domain, the TIN2-TBM 72 
interacts with a high affinity with the TRF1-TRFH domain and disruption of these 73 
residues in TIN2S has profound impact on TIN2S-TRF1 interactions in vivo (9). Whether 74 
the C-terminal TIN2L-extension influences TIN2's interaction with its shelterin binding 75 
partners has not been determined. Similar to the interaction studies, little is known 76 
regarding the functional contributions of TIN2L versus TIN2S at telomeres. 77 
Simultaneous loss of both TIN2 isoforms via knockdown has seemingly contradictory 78 
effects on telomerase regulation, due to destabilizing effects on TRF1, which is a 79 
negative regulator of telomere length (12), and decreased telomere association of 80 
TPP1, which is crucial for the recruitment of telomerase to the telomere (13).  81 
Gene mutations associated with human disease often provide insight into 82 
previously unrecognized protein function, which may be true for TIN2. TINF2, the gene 83 
that encodes TIN2, is the second most commonly mutated gene in the telomere biology 84 
disorder dyskeratosis congenita (DC) (14, 15). DC is a complex syndrome characterized 85 
by bone marrow failure and cancer predisposition, pulmonary fibrosis, and a multitude 86 
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of other clinical features. Underlying these medical problems are constitutionally very 87 
short telomeres (16). DC-associated TINF2 mutations are most frequently de novo, yet, 88 
strikingly result in drastically short telomeres within a single generation (15). This is in 89 
contrast to autosomal dominant mutations in TERT, the catalytic component of 90 
telomerase, or TERC, the integral RNA, which are most often inherited and result in 91 
progressively shorter telomeres and increasing disease severity or multisystem 92 
involvement in successive generations (17, 18). The basis for this rapid telomere 93 
shortening remains to be fully elucidated. Notably, all TINF2 mutations reported in 94 
patients with very short telomeres, whether missense, frameshift, or nonsense, map to a 95 
central 30 amino acid region (residues 269-298, DC-cluster), which is immediately C-96 
terminal to the TIN2-TBM and present in both TIN2S and TIN2L (8, 19-21) (Fig. 1A). 97 
While the most N terminal truncation was shown to decrease TIN2S binding to TRF1, 98 
no universal effect of these mutations on TIN2S binding to TRF1, TRF2, or TPP1 has 99 
been observed (22, 23). Thus, it has been suggested that the impact of the TIN2 100 
mutations could be on other interactions. 101 
Consistent with this, TIN2 binds heterochromatin protein 1 (HP1) via a binding 102 
motif within the DC-cluster region (TIN2 residues 283-287) (24). HP1 binds to H3 tails 103 
methylated at lysine 9 and, similar to TIN2 (8), is necessary for sister telomere cohesion 104 
(24). Some DC-associated mutations affect both HP1 binding and sister telomere 105 
cohesion, leading to the proposal that DC-associated mutations cause decreased sister 106 
telomere cohesion, resulting in a loss of telomere lengthening via homologous 107 
recombination during embryogenesis. However, frameshift/nonsense mutations C-108 
terminal to this binding motif would not be expected to reduce HP1 binding, as was 109 
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observed for the Q298Rfs mutation. Notably, missense mutations have only been found 110 
from residues 280-291, while frameshift and nonsense mutations have been found 111 
throughout this region. These frameshift and nonsense mutations would obliterate any 112 
specific functions of the C-terminal region of TIN2S and TIN2L and could result in the 113 
expression of a truncated protein lacking the TIN2L C-terminal domain, as has been 114 
shown for two such mutations (22). Our identification of a young child with DC, very 115 
short telomeres and an even more C-terminal K302Rfs mutation further raises the 116 
question of functions other than HP1 binding contributing to the very short telomeres 117 
observed in these patients. 118 
Additionally, it has been reported that while DC-associated TINF2 mutations do 119 
not affect overall telomerase activity, they do result in decreased telomerase activity 120 
immunoprecipitated with TIN2S (25). However, a mouse model in which a DC-121 
associated TINF2 mutation results in decreased telomere length even in the absence of 122 
the telomerase RNA component (26) indicates that defects in telomerase recruitment 123 
alone are unlikely to account for the much more severe phenotype seen in patients with 124 
TINF2 mutations.  125 
 Importantly, both TIN2L and TIN2S contain all known binding regions and the 126 
DC-cluster (10). Functions that may be unique or specific to TIN2L at the telomere and 127 
any effects of DC-associated mutations on those functions remain unexamined. We 128 
hypothesized that TIN2L has roles at the telomere not shared with the shorter isoform, 129 
and that those roles could be impacted upon by DC-associated mutations. Herein, we 130 
have identified differences in the ability of TIN2L and TIN2S to interact with TRF1 and 131 
TRF2, and a role for the DC-cluster and phosphorylation specifically in TIN2L 132 
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interactions. Additionally, we show that TIN2L and TIN2S overexpression have different 133 
effects on telomere length. These data suggest that TIN2S and TIN2L have differing 134 
roles within the shelterin complex and in telomere regulation, and that the composition 135 
of the shelterin complex could be fundamentally altered in patients with DC-associated 136 
TINF2 mutations. 137 
 138 
MATERIALS AND METHODS 139 
Comparative analysis of protein sequences 140 
We used a real-value ET method (27) to assign a score to the degree of conservation of 141 
protein residues from TIN2 orthologs reported by the Ensembl database (28). A BLAST 142 
search against the NCBI’s RefSeq (29) database, using the TIN2L sequence as the 143 
query, was performed to confirm results from the Ensembl database. We chose to base 144 
our analysis on mammalian sequences only, as Ensembl did not report any TIN2 145 
orthologs in vertebrates other than mammals and amphibians, and the BLAST search 146 
returned only mammalian sequences with matches to the last three exons of TIN2.  147 
Prediction of TIN2 phosphorylation and kinase-specific predictions 148 
Human TIN2L sequence (Uniprot identifier Q9BSI4-1) was analyzed using NetPhos3.1 149 
(30, 31), GPS3.0 (32), and PPSP (30) algorithms via their respective servers 150 
(http://gps.biocuckoo.org; http://www.cbs.dtu.dk/services/NetPhos/; 151 
http://ppsp.biocuckoo.org/; each accessed November 18, 2017).  152 
Vectors and mutagenesis 153 
The pcDNA3.1-flag-2xHA-TIN2S and pcDNA-flag-2xHA-TIN2S-R282H vectors have 154 
been previously described (22). The cDNA encoding the C terminus of TIN2L was 155 
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amplified from MGC-12628 (ATCC) and subcloned 3’ to the penultimate codon in 156 
pcDNA3.1-flag-2xHA-TIN2S to generate pcDNA3.1-flag-2xHA-TIN2L. pcDNA3.1-flag-157 
2xHA-TIN2L-R282H, pcDNA3.1-flag-2xHA-TIN2L-D391K+D395K, and pcDNA3.1-flag-158 
2xHA-TIN2L-DEEE(397-400)KKKK were generated using site directed mutagenesis as 159 
previously described (22). pLenti6.3-GFP, pLenti6.3-TIN2S, pLenti6.3-TIN2L, pLenti6.3-160 
TIN2L-S396A, and pLenti6.3-TIN2L-S396E were generously provided by Dr. Kenneth 161 
Scott (Baylor College of Medicine). The C termini of TIN2L-S396E and TIN2L-S396A 162 
were amplified from their respective pLenti6.3 vectors and subcloned 3’ to the 163 
penultimate codon in pcDNA3.1-flag-2xHA-TIN2S to generate pcDNA3.1-flag-2xHA-164 
TIN2L-S396E and pcDNA3.1-flag-2xHA-TIN2L-S396A. pLenti6.3-TIN2S-R282H was 165 
generated from pcDNA3.1-flag-2xHA-TIN2S-R282H via subcloning. pcDNA3.1-flag-166 
2xHA-TIN2L-R282H+S396A was generated via subcloning from plasmids containing the 167 
respective mutations. myc-TPP1 was amplified from pLpcx-myc-TPP1 (generously 168 
provided by Dr. Susan Smith, NYU) and subcloned into pcDNA3.1 to generate 169 
pcDNA3.1-myc-TPP1. TIN2L was amplified from pcDNA3.1-flag-2xHA-TIN2L and 170 
subcloned into pET28SUMO (generously provided by Dr. Ming Lei, University of 171 
Michigan) to generate pET28SUMO-TIN2L. TIN2L, TIN2L-D391K+D395K, and TIN2L-172 
R282H were amplified from their respective pcDNA3.1 vectors and subcloned into 173 
GCN4 leucine zipper-Venus 2 (C-terminal half; V2) to generate TIN2L-V2, TIN2L-174 
D391K-V2, and TIN2L-R282H-V2. V1-TRF2 and V2-RAD21 have been previously 175 
described (2). pcDNA3.1-myc-TRF1, pcDNA3.1-myc-TRF2, pcDNA3.1-myc-TRF2-176 
F120A, and pSP73Sty11 were all a generous gift from Dr. Titia De Lange (Rockefeller 177 
University). 178 
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Immunoblotting 179 
Cells were resuspended in ice cold lysis buffer (50 mM Tris-HCl at pH 7.5, 1 mM EDTA, 180 
400 mM NaCl, 1% Triton X-100, 0.1% SDS, 1 mM DTT, 1 mM PMSF and 1X protease 181 
inhibitor cocktail III [Calbiochem]) and incubated for 10 minutes on ice prior to addition 182 
of an equal amount of ice cold water. The lysates were then centrifuged at 4 ˚C and 183 
20,800 x g for 10 minutes, and the pellet was discarded. Protein concentration was 184 
determined using the BCA protein assay kit (Pierce). Lysates were resolved on 10% 185 
SDS-polyacrylamide gels and transferred to nitrocellulose membranes. The membranes 186 
were probed with at least one of these primary antibodies as indicated in the text: rabbit 187 
polyclonal -FLAG (Sigma-Aldrich), rabbit polyclonal -c-Myc (Sigma-Aldrich), rabbit 188 
polyclonal -TIN2 #865 (kindly provided by Dr. Titia De Lange, Rockefeller University), 189 
mouse monoclonal --actin (Sigma-Aldrich), rabbit polyclonal -TRF1 (Santa Cruz), 190 
rabbit polyclonal -TRF2 (Santa Cruz), rabbit polyclonal -POT1 (Abcam), or rabbit 191 
polyclonal -GFP (Abcam). The appropriate IRDye 800CQ conjugated secondary 192 
antibody (Li-Cor) was then used and blots were visualized using the Li-Cor Odyssey 193 
Infrared Imaging System. Blots were stripped by incubation in 0.1 M NaOH for 10 194 
minutes at room temperature and reprobed. Immunoblots were quantified using 195 
Odyssey v3.0 Software (Li-Cor). 196 
Phosphate affinity SDS-PAGE using Phos-tagTM 197 
Lysates were prepared as described above for immunoblotting, with the addition of 1x 198 
Phosphatase Inhibitor Cocktail II (Sigma-Aldrich) to the lysis buffer to prevent 199 
dephosphorylation. As a control, protein extracts were also prepared in the absence of 200 
phosphatase inhibitors and treated with 400 U of  phosphatase (NEB) for 30 minutes 201 
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at 30 C. Lysates were resolved on a 10% w/v acrylamide gel with 100 M Phos-tagTM 202 
(Wako) prepared according manufacturer’s instructions. Prior to transfer, the gel was 203 
soaked in transfer buffer with 1 mM EDTA for 10 minutes at room temperature with 204 
shaking. Subsequent steps were carried out as described above for immunoblotting. 205 
TIN2L protein purification 206 
Protein purification was conducted similarly to previously described for TIN2S, with 207 
slight modifications (9). Human TIN2L in a modified pET28b vector with a SUMO site 208 
between the 6Xhis tag and the N terminus of TIN2L was expressed in BL21(DE3) E. 209 
coli. Following induction with 0.1 mM IPTG, cells were grown for 24 hours at 16 C and 210 
then harvested by centrifugation. Cells were then resuspended in lysis buffer (50 mM 211 
phosphate buffer pH 7.2, 0.5 mM 2-mercaptoethanol, 10% glycerol, 1 mM PMSF, 400 212 
mM NaCl, 3 mM imidazole, 0.1 mg/mL lysozyme, 1X protease inhibitor cocktail set III 213 
[Calbiochem]) and lysed via sonication. The lysate was then cleared via centrifugation, 214 
and incubated overnight at 4 C with Ni-NTA agarose beads (Qiagen). The bead-lysate 215 
slurry was applied to a column and washed with 10 column volumes of wash buffer (50 216 
mM phosphate buffer pH 7.2, 0.5 mM -mercaptoethanol, 10% glycerol, 1 mM PMSF, 217 
400 mM NaCl, 20 mM imidazole) prior to addition of 1.5 column volumes of elution 218 
buffer (50 mM phosphate buffer pH 7.2, 0.5 mM -mercaptoethanol, 10% glycerol, 1 219 
mM PMSF, 400 mM NaCl, 250 mM imidazole, 1X protease inhibitor cocktail set III 220 
[Calbiochem]). The eluate was then concentrated using an Amicon Ultra 10K 221 
Centrifugal filter (Millipore) prior to separation on a HiLoad 16/600 Superdex 200 pg (GE 222 
Healthcare Life Sciences) gel filtration column equilibrated with gel filtration buffer (25 223 
mM Tris pH 8.0, 150 mM NaCl, 5 mM DTT). The fractions containing TIN2L were 224 
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pooled, concentrated using an Amicon Ultra 10K Centrifugal filter (Millipore), and stored 225 
at -80 C until use. 226 
In vitro phosphorylation 227 
Three micrograms of recombinant TIN2L purified from E. coli was incubated with 10 U 228 
of CK2 (NEB) and 10 Ci 32P-ATP in 1X CK2 reaction buffer (NEB) at 30C for 30 229 
minutes. As a control, 3 g of BSA (NEB) was incubated with CK2 under the same 230 
conditions. To confirm that the observed phosphorylation was carried out by CK2, the 231 
reaction was also performed in the presence of increasing concentrations of  4,5,6,7-232 
Tetrabromo-2-azabenzimidazole (TBB), a CK2 inhibitor. Following the phosphorylation 233 
reaction, proteins were resolved on a 10% SDS-PAGE gel, which was then exposed to 234 
a PhosphorImager screen. In vitro phosphorylation assays were also performed using 235 
flag tagged TIN2L or TIN2L-S396A partially purified from 293T cells. Twenty four hours 236 
after transfection with 5 g of DNA using lipofectamine and Plus (Invitrogen) according 237 
the manufacturer’s instructions, cells were lysed as described above. Phosphatase 238 
inhibitor cocktail II (Sigma-Aldrich) was added to one quarter of the lysate, which was 239 
set aside as a control. The remainder of the lysate was treated with 400 U of  240 
phosphatase (NEB) for 30 minutes at 30C. The phosphatase was then inactivated by 241 
the addition of 50 mM EDTA and 1X phosphatase inhibitor cocktail II (Sigma-Aldrich).  242 
The lysates, including the reserved control, were then incubated overnight at 4 C with 243 
mouse monoclonal -FLAG M2 magnetic beads (Sigma-Aldrich) to isolate flag tagged 244 
TIN2L or TIN2L-S396A. Beads were washed four times with a 1:1 dilution of lysis buffer, 245 
and then resuspended in 1X CK2 buffer (NEB) supplemented with 200 M ATP, 1X 246 
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phosphatase inhibitor cocktail II (Sigma-Aldrich), 1X protease inhibitor cocktail III 247 
(Calbiochem) and the indicated amount of CK2. Phosphorylation was carried out at 30 248 
C for 30 minutes, prior to analysis using phosphate affinity SDS-PAGE with Phos-249 
tagTM. 250 
Co-immunoprecipitation 251 
Co-immunoprecipitations were conducted similarly to previously described (7). For TIN2 252 
co-immunoprecipitations with TRF1, TRF2, or TPP1, 3 x 106 HEK 293T cells were co-253 
transfected with 5 g of each plasmid using the lipofectamine and Plus reagents 254 
(Invitrogen) according to the manufacturer’s instructions. Twenty four hours after 255 
transfection, the cells were lysed as described above for immunoblotting. Half a percent 256 
of the supernatant was reserved as input. Supernatants were incubated overnight at 4 257 
C with 60 L of mouse monoclonal -FLAG M2 magnetic beads (Sigma-Aldrich) or 2 258 
g mouse monoclonal -Myc 9E10 (Abcam). For myc pull downs, 60 L of Protein G 259 
Plus-agarose beads (Calbiochem) were added during the final hour. Beads were 260 
washed four times with a 1:1 dilution of lysis buffer prior to elution with Laemmli loading 261 
buffer. Proteins were analyzed by immunoblotting. Western blots were quantified using 262 
Odyssey V3.0 (LiCor). 263 
Protein complementation assay 264 
The protein complementation assay was carried out as previously described (2). 265 
Stable overexpression cell lines 266 
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HT1080 cells were infected with pLenti6.3-GFP, pLenti6.3-TIN2S, pLenti6.3-TIN2S-267 
R282H, pLenti6.3-TIN2L, pLenti6.3-TIN2L-S396A, or pLenti6.3-TIN2L-S396E lentivirus 268 
produced in HEK293T cells. HT1080 cells overexpressing the genes of interest were 269 
then selected by incubation with selection media containing blasticidin. Beginning two 270 
weeks after initial viral induction (time point 0), cells were counted and plated every 3-4 271 
days to follow growth and population doublings, and cells pellets were saved at -80 C 272 
for further analysis.  273 
Measurement of telomere length 274 
Measurement of bulk telomere terminal restriction fragment length was determined by 275 
Southern blotting as previously described (33) with the following specifications. 276 
Genomic DNA was isolated using the DNeasy Blood and Tissue kit (Qiagen) and 277 
subjected to digestion with HinfI, RsaI, and RNase A (NEB). Digested DNA was 278 
separated on a 1% agarose gel via pulse field gel electrophoresis and then transferred 279 
to a Zetaprobe GT Membrane (Bio-Rad) for detection of telomeric sequence by 280 
hybridization with an 800 bp telomeric probe derived from pSP73Sty11 fragment labeled 281 
with 32P-dCTP using Klenow fragment (34). Telomere length was determined using 282 
ImageQuant software (GE Healthcare Life Sciences) and Telorun 283 
(http://www4.utsouthwestern.edu/cellbio/shay-wright/research/sw_lab_methods.htm). 284 
 Single telomere length analysis (STELA) at 17p and XpYp was performed as 285 
previously described (35).  286 
CRISPR/Cas9 cell line creation 287 
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Guide RNAs (gRNAs) targeting exons 7 and 8 of the TINF2 locus were designed using 288 
the CRISPR Design tool (http://crispr.mit.edu/) (36). Three guides with quality scores of 289 
76 or greater were chosen. Cleavage efficiency of the gRNAs was determined using the 290 
Guide-it mutation detection kit (Takara) according to manufacturer’s instructions. 291 
HT1080 and Flp-In T-REx cell lines were transfected with 5 g of pGS-gRNA-Cas9-292 
Puro (Genscript) containing the desired gRNA using lipofectamine and Plus (Invitrogen) 293 
according to the manufacturer’s instructions. Two days after transfection, the host cell 294 
line was diluted and plated to form colonies. After expansion of the clones, 48 colonies 295 
from each gRNA were screened for mutations in the TINF2 gene initially by sequencing 296 
PCR products amplified from the surrounding genomic region. Those with products with 297 
abnormal sequences were TopoTA cloned and 10 TopoTA clones sequenced to 298 
determine the sequences on each allele. Cells from colonies of interest were counted 299 
and plated every 3-4 days to follow growth and population doublings, and cell pellets 300 
were saved at -80 C for further analysis.  301 
Isolation of endogenous nuclear complexes 302 
HeLa cell nuclear complexes were examined as previously described (37). Briefly, 303 
nuclei from 7x109 HeLa cells were extracted using 0.5 M KCl (38). Extracts were 304 
dialyzed into S-300 buffer (50 mM Tris pH 7.5, 150 mM KCl, 0.2 mM EDTA, 0.025% 305 
NP-40, 0.5 M dithiothreitol, 1X cOmplete protease inhibitor [Roche]) and clarified by 306 
centrifugation. The dialyzed sample was concentrated using an Amicon Ultra 10K 307 
Centrifugal filter (Millipore) prior to fractionation on a HiLoad 16/600 Superdex 200 pg 308 
(GE Healthcare Life Sciences) gel filtration column equilibrated with S-300 buffer. Half 309 
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milliliter fractions were taken beginning at 30 mL elution volume and analyzed by 310 
immunoblotting. 311 
Telomere chromatin immunoprecipitation 312 
Cells were fixed in 1% formaldehyde for 30 minutes at room temperature followed by 313 
lysis in RIPA buffer (50 mM Tris-HCl at pH 8, 5 mM EDTA, 150 mM NaCl, 0.5% sodium 314 
deoxycholate, 1% NP-40, 0.1% SDS, 1 mM PMSF and 1X protease inhibitor cocktail III 315 
[Calbiochem]). The lysates were sonicated in a Diagenode Bioruptor for 10 minutes, 3 316 
times at high setting to generate ~1 kb DNA fragments. Cellular debris was pelleted by 317 
centrifugation at 4 ˚C and 20,000 g for 10 minutes, and the protein concentration 318 
assessed using the BCA protein assay kit (Pierce). For immunoprecipitation 600 μg of 319 
the lysate was incubated with the corresponding antibodies (3 μg) overnight at 4 C: 320 
rabbit-TRF2 (Novus, NB110-57130), rabbit -TRF1 (Abcam, ab1423), rabbit IgG 321 
(Santa Cruz). The next day, 45 µl of protein G magnetic beads (Pierce) were added and 322 
after 2 hours, the beads were washed 2X in RIPA buffer, 4X in wash buffer (100 mM 323 
Tris-HCl pH 8.5, 500 mM LiCl, 1% NP-40, 1% sodium deoxycholate) and another 2X in 324 
RIPA buffer. Following two washes in 1X TE, proteins were eluted in 1XTE/1% SDS and 325 
incubated in 65 C overnight to reverse the crosslinks. The samples were then treated 326 
with RNase A (20 μg) and Proteinase K (40 μg) and subjected to phenol-chloroform 327 
extraction. After ethanol precipitation, dot blotting was performed on a Zeta-probe 328 
membrane (Bio-Rad) to hybridize the DNA with an 800 bp radiolabeled TTAGGG probe 329 
to assess the amount of immunoprecipitated telomeric DNA. A 5′ 32P-labeled 330 
oligonucleotide Alu probe was used as negative control. ImageQuant software was 331 
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used to quantify the signal intensity of telomeric or Alu IP relative to the corresponding 332 
input signals.  333 
Cell line authentication 334 
Cell lines were authenticated by short tandem repeat DNA analysis at MD Anderson 335 
Cancer Center Characterized Cell Line Core Facility (September 1, 2017).  336 
RESULTS 337 
TIN2L is phosphorylated by casein kinase 2 (CK2). To examine whether TIN2L 338 
contains regions potentially important for function that are not present in the more 339 
commonly studied shorter isoform (TINS), we first estimated conservation of residue 340 
types across mammalian orthologs of TIN2L (see Materials and Methods). The 341 
estimated degree of conservation is collated in Figure 1A below the approximate or 342 
delineated TIN2 binding regions determined previously by crystallography, yeast two 343 
hybrid, far-western, and co-immunoprecipitation experiments (7, 8, 19, 20). While much 344 
of the TIN2 sequence is highly variable, we found conserved regions are present and 345 
some coincide with the known interaction regions of TIN2. In particular, region 258 to 346 
267, which contains the TBM and is sufficient for high affinity TRF1 but not TRF2 347 
interaction (9), consists almost entirely of residues that are identical across all 348 
mammalian sequences. A large fraction of the residues within the N terminal TRFH 349 
domain are also highly evolutionarily constrained. Lastly, within the 30 aa region 350 
spanning residues 269 to 298, where all of the DC-associated TIN2 mutations have 351 
been reported to date (indicated as DC in Fig. 1A), only residues 280 to 291 showed 352 
signs of evolutionary constraint, coinciding with the HP1 binding motif (residues 283-353 
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287). In addition to the evolutionary constraint in these regions shared by TIN2S and 354 
TIN2L, we identified two highly evolutionarily constrained regions within the C-terminal 355 
domain exclusive to TIN2L (TIN2L CTD) (Fig. 1A). The region consisting of residues 356 
388-400 was the more highly constrained of the two. 357 
Within this region are residues 396SDEE399, which conform to a casein kinase 2 (CK2) 358 
recognition motif (S/T-X-X-E/D, where X represents non-basic residues) targeting 359 
phosphorylation of S396 (39, 40). The prediction for S396 phosphorylation and its 360 
phosphorylation by CK2 was robust across several protein phosphorylation prediction 361 
algorithms including NetPhos3.1 (30, 31), GPS3.0 (32), and PPSP (30). These residues 362 
were conserved across mammalian orthologs reported in the Uniprot database (Fig. 363 
S1). Further supporting these data, endogenous TIN2L was previously found to be 364 
phosphorylated at S396 in human embryonic stem cells using high throughput mass 365 
spectrometry (41). Unlike humans, mice express only one isoform of TIN2 (10). Mouse 366 
TIN2 includes a C-terminal region with high similarity to the C-terminal extension in 367 
human TIN2L, and the cognate residue to human S396, mouse S380, was also found to 368 
be phosphorylated in three separate mass spectrometry analyses (42-44). 369 
CK2 is known to phosphorylate TRF1 (45). This phosphorylation of TRF1 is necessary 370 
for its stability, binding to telomeric DNA, and homodimerization, thereby contributing to 371 
the negative length regulation of telomeres. Because CK2 is important for the telomeric 372 
function of TRF1 and a putative CK2 phosphorylation site is present in TIN2L, we asked 373 
if TIN2Lis phosphorylated and, if so, by CK2. To determine if TIN2L is phosphorylated, 374 
we utilized the reagent Phos-tagTM, which retards the migration of phosphorylated 375 
proteins through SDS-polyacrylamide gels (46). First, we analyzed transiently 376 
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expressed, tagged proteins in HEK 293T cells and found that TIN2L migrated more 377 
rapidly through the gel following  phosphatase treatment, indicating that the majority of 378 
TIN2L was phosphorylated (Fig. 1B). While TIN2S can be phosphorylated (47), the 379 
migration of TIN2S was unaffected by  phosphatase treatment, indicating that this 380 
isoform is not predominantly phosphorylated in asynchronous cells (Fig. 1B) Charge 381 
swapping mutations in the CK2 recognition site (D391K+D395K and DEEE397-382 
400KKKK) and mutation of S396 to either a phosphomimetic (S396E) or phosphodead 383 
(S396A) residue abolished TIN2L phosphorylation (Fig. 1C). The most common 384 
missense mutation in DC, R282H, did not affect TIN2L phosphorylation (Fig. 1C).  385 
CK2 is an essential kinase. Inhibition of CK2, via either RNA interference or the CK2-386 
selective chemical inhibitor TBB, results in apoptosis, making it difficult to study 387 
phosphorylation by CK2 in an endogenous context (48). To overcome this and establish 388 
whether CK2 might be responsible for the observed TIN2L phosphorylation, we purified 389 
recombinant tagged TIN2L from E. coli and determined the ability of recombinant CK2 390 
purified from E. coli (NEB, Fig. 1D) to phosphorylate this TIN2L in vitro. TIN2L was 391 
phosphorylated by CK2 in the presence of [32P]-ATP, as indicated by the presence of 392 
radiolabeled TIN2L (Fig. 1E). This phosphorylation decreased in the presence of TBB, 393 
which drastically inhibits CK2 but not 33 other kinases (49), indicating that TIN2L 394 
phosphorylation was CK2 dependent. To determine if the residue phosphorylated by 395 
CK2 was S396, we overexpressed TIN2L or TIN2L-S396A in 293T cells, treated the cell 396 
lysates with  phosphatase to remove any existing phosphorylations, partially purified 397 
TIN2 via immunoprecipitation, and then incubated it with recombinant CK2. 398 
Phosphorylation status was then determined using SDS-PAGE in the presence of Phos-399 
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tagTM, followed by western blotting. Immunoprecipitated TIN2L not subjected to  400 
phosphatase treatment was prepared as a control. As shown in Figure 1F, wild type 401 
TIN2L was phosphorylated by CK2, while TIN2L-S396A was not. In summary, these 402 
data showed highly conserved residues corresponding with a CK2 recognition site in 403 
TIN2L, loss of phosphorylation of tagged expressed TIN2L upon mutation of the site in 404 
cells, and in vitro phosphorylation of wild type, but not mutant, partially purified TIN2L by 405 
CK2 and which was reduced by a highly specific CK2 inhibitor. Combined with the 406 
previous mass spectrometry data indicating S396 is phosphorylated in both mouse and 407 
human cells, this data strongly supports the notion that TIN2L-S396 is phosphorylated 408 
by CK2 in vivo.  409 
The DC cluster and TIN2L phosphorylation enhance TIN2L's association with 410 
TRF2 in vivo. To determine the molecular effects of TIN2L phosphorylation, we 411 
examined the ability of transiently expressed epitope tagged TIN2L to interact with the 412 
known TIN2S shelterin binding partners, which were also transiently expressed and 413 
epitope tagged, and the effect of mutation of the phosphorylation site on those 414 
interactions via co-immunoprecipitation. We also compared TIN2L interactions with that 415 
of TIN2S and the effect of the DC R282H mutation on TIN2L as compared to TIN2S 416 
interactions. Interestingly, TIN2L interacted much more robustly with TRF2 than TIN2S 417 
(Fig. 2A, quantified in Fig. 2D). This is in contrast to what was previously published (10). 418 
However, as shown in Figure 2D, this result was very reproducible with consistent 419 
results across multiple biological replicates. As previously reported, the most common 420 
missense mutation in TIN2 in DC patients, R282H, had no effect on TIN2S binding to 421 
TRF2 (Fig. 2A, quantified in Fig. 2D) (22, 23, 26). In contrast, the R282H mutation 422 
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reduced TIN2L binding to TRF2 to levels similar to that of wild type TIN2S, indicating an 423 
effect of the DC cluster that is manifest only within the context of the long isoform. 424 
Similarly, the phosphodead mutation greatly reduced TIN2L binding to TRF2, while the 425 
phosphomimetic mutation did not, indicating that TIN2L phosphorylation at S396 is 426 
critical for this enhanced interaction (Fig. 2B, quantified in Fig. 2D). The double mutant 427 
TIN2L-R282H+S396A did not decrease TRF2 binding beyond either mutation alone, 428 
indicating that the DC-cluster and TIN2L phosphorylation site cooperate to enhance 429 
TRF2 binding to TIN2L (Fig. 2C, quantified in Fig. 2D).  430 
The importance of S396 phosphorylation and R282 in TIN2L-TRF2 interaction was also 431 
observed using the protein-fragment complementation assay (PCA), with TIN2L and 432 
TRF2 fused with the C- (denoted as V2) and N- (denoted as V1) terminal halves of the 433 
Venus yellow fluorescent protein variant, respectively. In this type of PCA, fluorescence 434 
is only detected when the proteins to which the split Venus halves are tagged come into 435 
close proximity, allowing reconstitution of N- and C-terminal fragments of the Venus 436 
yellow fluorescent protein (50). The fluorescence observed with co-transfection of 437 
TIN2L-V2 with V1-TRF2 was markedly reduced with the TIN2L-R282H-V2 and TIN2L-438 
D391K+D395K-V2, which abolishes TIN2L phosphorylation (Fig. 1C), mutants (Fig. 3), 439 
consistent with a decreased interaction of these TIN2L mutants with TRF2. We found 440 
expression of TIN2S and TIN2L differed greatly in these constructs, so the interaction 441 
between the TIN2 isoforms and TRF2 could not be compared using PCA.  442 
We next determined if the increased interaction of TRF2 with TIN2L involves the TRF2 443 
TRFH domain. To do this, we employed a TRF2 TRFH domain mutation, F120A. TRF2-444 
F120A was shown previously by transient transfection and co-immunoprecipitation to 445 
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have no impact on TIN2S’s interaction with TRF2, whereas mutation of the cognate 446 
residue in the TRF1 TRFH domain, F142A, drastically reduced TIN2S’s interaction with 447 
TRF1. Nonetheless, the conformations of the TIN2-TBM bound to the TRFH domains of 448 
TRF1 and TRF2 are similar (9) and, in one study, TRF2-F120A was been shown to 449 
reduce transiently transfected TRF2's ability to interact with endogenous TIN2, although 450 
it was not determined if this was TIN2S or TIN2L (51). Reproducibly in our assays and 451 
in contrast to what was observed by transient transfection and co-immunoprecipitation 452 
for TRF2-F120A and TIN2S, we found that the TRF2-F120A mutation decreased 453 
TIN2L’s binding to TRF2 (Fig. 4). This suggests that the CTD of TIN2L stabilizes the 454 
TIN2-TBM - TRF2-TRFH interaction in vivo.  455 
TIN2L binds less robustly than TIN2S to TRF1 but equivalently to TPP1. We next 456 
examined how TRF1 interacted with TIN2L relative to TIN2S using transient expression 457 
and co-immunoprecipitation. Conversely and in striking contrast to TRF2, TRF1 458 
interacted much more robustly with TIN2S than TIN2L (Fig. 5A, quantified in Fig. 5B). 459 
The R282H mutation had no effect on TIN2S binding to TRF1, but reduced TIN2L’s 460 
ability to bind TRF1 even further. However, TIN2L phosphorylation appeared to play no 461 
role in interaction with TRF1 (Fig. 5A and B), unlike with TRF2 (Fig. 2B and D). 462 
Lastly, having found that TRF2 interacted more robustly with TIN2L than TIN2S, and, 463 
conversely, TRF1 interacted more robustly with TIN2S than TIN2L, we next examined 464 
how the isoforms interacted with TIN2's third shelterin binding partner, TPP1.  In 465 
contrast to TRF1 and TRF2, we found both isoforms interacted at similar levels with 466 
TPP1 in the co-immunoprecipitation assays  (Fig. 5C, quantified in Fig. 5D).  467 
 22 
To explore whether TIN2L is present in endogenous shelterin complexes, we subjected 468 
the nuclear fraction from a HeLa cell lysate to size based fractionation under physiologic 469 
ionic strength using a gel filtration column. As previously reported, endogenous TIN2S, 470 
TRF1, TRF2, and POT1 co-fractionated over a range of molecular masses larger than 471 
670 kDa (Fig. 6) (7, 37, 52), which is larger than the size of a core shelterin complex, 472 
consisting of TIN2S, TRF2 homodimer, POT1, and TPP1 (306 kDa) (53), TRF1 473 
homodimer (115 kDa) (53) and 2 RAP1 molecules (expected 88 kDa). TIN2L was also 474 
present in these fractions, consistent with it being in a complex with the shelterin 475 
components. Given the larger than expected cumulative size of the proteins that co-476 
fractionated, TIN2S and TIN2L could simultaneously be present within a single shelterin 477 
complex. 478 
TIN2L is neither required for viability nor normal telomere length maintenance in 479 
transformed cell lines. Given the differences in shelterin component binding between 480 
TIN2L and TIN2S, we next sought to determine if they might also differentially impact 481 
telomere length regulation. The role of TIN2L S396 phosphorylation in telomere length 482 
regulation was of particular interest given CK2’s role in telomere length regulation via its 483 
phosphorylation of TRF1 (37). First, we stably overexpressed TIN2S, TIN2S-R282H, 484 
TIN2L, TIN2L-S396A, TIN2L-S396E or a GFP control in the HT1080 cell line and 485 
determined the telomere length by Southern blot over successive population doublings 486 
(Fig. 7). We found that the telomeres progressively elongated in the HT1080 GFP 487 
control cells. Telomere elongation in this control cell line has been observed by others 488 
(19, 21, 25, 26, 34), and may reflect resetting of telomere length in sublines that had 489 
previously undergone stochastic shortening. While telomeres progressively elongated in 490 
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the GFP control cell lines, overexpression of either TIN2S or TIN2S-R282H inhibited 491 
this progressive elongation, consistent with previous reports demonstrating impairment 492 
of telomere maintenance upon TIN2S overexpression (24, 25). In contrast, telomeres 493 
continued to progressively elongate in cells overexpressing wild type TIN2L, which was 494 
a consistent observation in separately generated cell lines (Fig. 7 and S2). This result 495 
could indicate that TIN2L simply lacks activity (as with GFP) or specifically lacks the 496 
inhibitory activity of TIN2S. However, whereas telomeres also progressively elongated 497 
in cells overexpressing TIN2L with the phosphomimetic S396E mutation, they did not in 498 
cells overexpressing TIN2L with the phosphodead S396A mutation (Fig. 7 and S3). The 499 
differences in telomere length changes could not be attributed to differences in levels of 500 
overexpression, which were equivalent in each of the cell lines (Fig. 7C, S2, and S3) nor 501 
to differences in population doubling time or cumulative population doublings for the cell 502 
lines, which were equivalent (Fig. S4). Taken together, these results are most 503 
consistent with the wild type TIN2L lacking inhibitory activity and the S396A mutation 504 
resulting in TIN2L becoming TIN2S-like with respect to telomere length regulation, 505 
similar to the effect it has on TIN2L's TRF2 binding (Figs. 2B and 2D). 506 
To explore the role of endogenous TIN2L in telomere length regulation, we used the 507 
CRISPR/Cas9 system (54) to modify the genomic TINF2 locus. We designed guide 508 
RNAs that targeted TIN2L-specific exons 7 and 8 for mutagenesis (Fig. S5A and B), 509 
thereby creating cell lines that still encoded TIN2S, but either no longer encoded TIN2L 510 
protein or encoded a protein that was truncated N-terminal to S396. We characterized 511 
four unique compound heterozygous cell lines, three in the HEK 293-derived Flp-In T-512 
REx cell line and one in the HT1080 cell line (Fig. S5C). Clonal lines that were isolated 513 
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but found to not contain mutations in TINF2 served as controls. The Flp-In T-REx lines 514 
285-F3 and 285-F10 had frameshift mutations in exon 7 of each allele, whereas the cell 515 
line 286-R had frameshift mutations in exon 8, N terminal to S396. The HT1080 lines 516 
286-6A, 286-6B, and 286-6C, which were derived from the same clone, had an in frame 517 
deletion of 15 bp, encoding a protein lacking amino acids 387-392, and a frameshift 518 
mutation encoding a protein truncated at amino acid 394. 519 
The TIN2L deficient clones were viable, although some clones exhibited decreased 520 
growth compared to WT (Fig. S6). STELA analysis, which provides a sensitive measure 521 
of changes in telomere length, revealed that the average 17p or XpYp telomere length 522 
in independently derived clones varied within the range observed in clones with intact 523 
TIN2L and over successive population doublings (Figs. 8 and S7). These results 524 
suggest that in these telomerase-positive cancer (HT1080) and transformed (Flp-In T-525 
REx) cell lines, TIN2L is neither required for viability nor normal telomere length 526 
maintenance.  527 
In contrast to our approach, Kim et al., studied the effect of CRISPR/Cas9 knockout of 528 
both TIN2 isoforms in HeLa cells (55). They found that loss of both TIN2 isoforms 529 
results in a reduction in TRF2 but not TRF1 association with telomeres in chromatin 530 
immunoprecipitation assays. Therefore, we determined the effect of loss of TIN2L 531 
protein alone on the association of TRF2 with telomeres. Although TIN2L interacted 532 
preferentially with TRF2 in co-IP experiments (Fig. 2), the absence of intact TIN2L 533 
protein had no impact on the telomere association of TRF2 (Fig. 9). The interaction of 534 
TRF1 with telomeres was similarly unaffected. Together with the telomere length data, 535 
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these results suggest that TIN2L and TIN2S have redundant functions in these cell 536 
lines. 537 
DISCUSSION 538 
Prior studies have focused on the shorter isoform of TIN2, however, our data reveal 539 
differences in the interactions of TIN2S and TIN2L with TRF1 and TRF2, suggesting 540 
that the composition of the shelterin complex and the interactions within may be even 541 
more complex than previously thought (7, 37, 53, 56).  Although previous studies have 542 
indicated that DC-associated mutations do not uniformly impact TIN2S interaction with 543 
TRF1, TRF2 and TPP1 (22, 23), the impact of the most common DC-associated 544 
mutation on TIN2L's ability to bind to both TRF1 and TRF2 leaves open the possibility 545 
that the composition of the shelterin complex may be fundamentally altered in patients 546 
with TINF2 mutations, potentially contributing to their devastatingly short telomeres. 547 
Herein, this study demonstrates that the increased interaction between TIN2L and 548 
TRF2, in comparison to TIN2S, requires the residue most commonly mutated in DC, 549 
R282, as well as phosphorylation of S396, and that R282 and phospho-S396 cooperate 550 
or redundantly promote this enhanced interaction (Figs. 2 and 3). These findings were 551 
unexpected as the primary TRF2 binding region in TIN2S resides within its N terminal 552 
TRFH-domain (11, 20) and the most common mutation in DC has no effect on TIN2S-553 
TRF2 interaction (22, 23, 26). Additionally, we found that the TRF2-TRFH domain is 554 
required for this increased interaction, which was similarly unexpected based on the 555 
lack of impact of the TRF2-F120A mutation on TIN2S-TRF2 interaction in vivo (9). How 556 
the TIN2L-specific C-terminal domain influences TRF2 binding remains to be 557 
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determined. As this region is predicted to be intrinsically disordered, structural studies 558 
will likely prove challenging. 559 
While overexpression of TIN2S inhibited progressive telomere elongation in HT1080 560 
cells, overexpression of TIN2L did not (Figs. 7 and S3). It is interesting to consider the 561 
possible mechanisms for this difference in light of protein-protein interaction data. It has 562 
previously been shown that TIN2S prevents inactivation of TRF1 via inhibition of poly-563 
ADP ribosylation of TRF1 by tankyrase (12). TRF1 is a negative regulator of telomere 564 
length (34). Since TRF1 interacts much more robustly with TIN2S than TIN2L (Fig. 5A 565 
and B), the discrepancy in telomere length maintenance could be due to effects on 566 
TRF1. Overexpression of TIN2L with a phosphodead mutation also inhibited 567 
progressive telomere elongation (Figs. 2 and S3). If the failure of telomeres to elongate 568 
in cells overexpressing TIN2S is indeed due to TRF1 stabilization, this is unlikely to be 569 
the mechanism for TIN2L-S396A mediated failure of telomere elongation, since TIN2L 570 
wild type and S396A interacted with TRF1 at similar levels (Fig. 5A and B).  It is 571 
therefore possible that phosphorylated TIN2L has a role in telomere maintenance 572 
unique from either TIN2S or unphosphorylated TIN2L.  573 
When endogenous full length TIN2L was eliminated using the CRISPR/Cas9 system, no 574 
consistent effect on telomere length was observed, which was surprising given the 575 
highly conserved CK2 consensus site within this region. While it is possible that TIN2S 576 
and TIN2L have redundant functions in telomere length maintenance, it is equally 577 
possible that TIN2L has other roles in telomere function. For example, we found TIN2L 578 
interacts with TRF2 via F120 (Fig. 4), a residue within its TRFH domain that is known to 579 
be critical for TRF2 binding to Apollo and SLX4 (9, 57). We speculate that TIN2L may 580 
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compete with these or other proteins that bind TRF2 via the TRFH domain. Therefore, 581 
in patients with the R282H mutation, the reduced interaction of TIN2L with TRF2 could 582 
result in a reduction in TIN2L binding to TRF2 at the telomere, thereby allowing 583 
increased recruitment of Apollo (58), SLX4 (57) or other factors that may drive telomere 584 
shortening. Future studies will address this hypothesis. 585 
Due to the difficulties in exploring the interactions of each isoform and multiple 586 
mutations with TRF1, TRF2 and TPP1 in an endogenous setting, these results were 587 
obtained using a transient transfection system with epitope tagged proteins expressed 588 
at higher than endogenous levels.  The use of epitope tagging of TIN2S and TIN2L was 589 
necessary as any antibody designed to bind TIN2S would also, by necessity, bind to 590 
TIN2L. This may raise concern that the differential interactions are directly or indirectly 591 
the result of the overexpression. However, using the same set of constructs expressed 592 
at the same level under identical conditions in both co-IP and PCA, we observed 593 
isoform- and allele-specific effects that suggest targeted impact on protein interaction. 594 
TIN2S and TIN2L interacted similarly with TPP1 and the interaction was not impacted 595 
by either R282H or S396A. Yet we observed very specific results with TIN2S and TIN2L 596 
interactions with TRF1 and TRF2, and very specific effects of R282H or S396A on 597 
TIN2S and TIN2L interactions. This suggests the differential interactions observed were 598 
unlikely to be due to nonspecific effects such as aggregation.  599 
This study indicates that the two TIN2 isoforms preferentially interact with different 600 
members of the shelterin complex. We therefore anticipate that they could play different 601 
roles in telomere regulation. These data indicate that the most common DC-associated 602 
TINF2 mutation greatly affects the ability of TIN2L, but not TIN2S, to interact with 603 
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members of the shelterin complex. While the field has largely overlooked the longer 604 
isoform of TIN2, future studies will need to take both isoforms into account.  605 
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FIGURE LEGENDS 813 
Figure 1. TIN2L phosphorylation is dependent upon an intact CK2 consensus site. (A) 814 
Evolutionary trace analysis and summary of known interaction regions in TIN2. The 815 
residues comprising the putative CK2 phosphorylation sites are displayed. The protein 816 
interaction domains, the region where all DC causing mutations cluster (DC), the 817 
position of R282 (*), and the putative TBM, all of which are present in both the TIN2L 818 
and TIN2S isoforms, and the C-terminal domain unique to TIN2L (TIN2L CTD) are 819 
indicated. (B) Characterization of TIN2S and TIN2L phosphorylation. Flag tagged TIN2S 820 
or TIN2L was analyzed by SDS-PAGE in the presence of Phos-tag reagent. 821 
Phosphorylated TIN2L (TIN2LP) is visible as a supershift compared to the  822 
phosphatase-treated TIN2L. (C) Characterization of TIN2L phosphorylation at S396 as 823 
in (B). (D) Recombinant CK2 (NEB) analyzed by SDS-PAGE and silver staining. M, 824 
protein molecular weight marker; 1, CK2 (E) In vitro phosphorylation of TIN2L by CK2. 825 
Recombinant TIN2L purified from E. coli was incubated with CK2 and [-32P]-ATP in the 826 
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absence or presence of a CK2 inhibitor (TBB). (F) In vitro phosphorylation of partially 827 
purified TIN2L and TIN2L-S396A by CK2. Flag tagged TIN2L or TIN2L-S396A from 828 
transiently transfected 293T cells was dephosphorylated by incubation with  829 
phosphatase, purified via immunoprecipitation, and incubated with CK2. 830 
Phosphorylation status was assessed by SDS-PAGE in the presence of the Phos-tag 831 
reagent and compared to non- phosphatase treated controls. 832 
Figure 2. S396 phosphorylation and R282 cooperate to promote TIN2L binding to 833 
TRF2. (A) Representative co-IP of TRF2 with co-transfected wild type TIN2S/L or 834 
TIN2S/L-R282H. (B) Representative co-IP of TRF2 with co-transfected wild type 835 
TIN2S/L, phosphomimetic TIN2L (S396E) or phosphodead TIN2L (S396A). (C) 836 
Representative co-IP of TRF2 with co-transfected wild type TIN2S/L, TIN2L-R282H, 837 
TIN2L-S396A, or double mutant TIN2L-R282H+S396A. (D) Quantification of (A), (B), 838 
and (C). For quantification, the amount of TRF2 co-immunoprecipitated was divided by 839 
the amount of TIN2 immunoprecipitated in order to account for any differences in TIN2 840 
expression/pull down. For each experiment, the value was then normalized to that of 841 
TIN2S. Error bars represent the standard deviation (SD) of several separate co-IP 842 
experiments. * p<0.008. 843 
Figure 3. The protein complementation assay confirms the effects of the R282H 844 
mutation and a phosphorylation site mutation on TIN2L interaction with TRF2. (A) 845 
Quantification of fluorescence from co-expression of V1-TRF2 with TIN2L-V2, TIN2L-846 
D391K+D395K-V2 or TIN2L-R282H-V2. Error bars represent the SD of three separate 847 
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transfections each measured in triplicate. *p<0.001. (B) Western blot exhibiting 848 
expression of the proteins assayed in (A). 849 
Figure 4. Interaction of TIN2L with TRF2 requires TRF2-F120. (A) Representative co-IP 850 
of TIN2S or TIN2L co-transfected with TRF2 or TRF2-F120A. (B) Quantification of (A). 851 
Error bars represent the SD of several separate co-IP experiments. For quantification, 852 
the amount of TRF2 co-immunoprecipitated was divided by the amount of TIN2 853 
immunoprecipitated in order to account for any differences in TIN2 expression/pull 854 
down. For each experiment, the value was then normalized to that of TIN2S. * p<0.05.  855 
Figure 5. TIN2L interacts less robustly with TRF1 than TIN2S, but both isoforms 856 
interact at similar levels with TPP1. (A) Representative co-IP of TRF1 co-transfected 857 
with wild type TIN2S/L, TIN2S/L-R282H, and TIN2L-S396A. (B) Quantification of (A). 858 
For quantification, the amount of TRF1 co-immunoprecipitated was divided by the 859 
amount of TIN2 immunoprecipitated in order to account for any differences in TIN2 860 
expression/pull down. For each experiment, the value was then normalized to that of 861 
TIN2S. Error bars represent the SD of several separate co-IP experiments. * p <0.02 862 
(C) Representative co-IP of TPP1 co-transfected with wild type TIN2S/L, TIN2S/L-863 
R282H, and TIN2L-S396A. (D) Quantification of (C). For quantification, the amount of 864 
TPP1 co-immunoprecipitated was divided by the amount of TIN2 immunoprecipitated in 865 
order to account for any differences in TIN2 expression/pull down. For each experiment, 866 
the value was then normalized to that of TIN2S. Error bars represent the SD of several 867 
separate co-IP experiments. 868 
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Figure 6. Endogenous TIN2L co-fractionates with other shelterin components in HeLa 869 
cell nuclear extract. (A) Western blot analysis of shelterin components from size based 870 
fractionation of HeLa cell nuclear lysate. HeLa cell nuclear extracts were subjected to 871 
gel filtration, and 0.5 mL fractions were taken beginning at 30 mL elution volume. 50 L 872 
aliquots were taken from the indicated fractions and analyzed for the presence of TIN2, 873 
TRF1, TRF2, and POT1 by immunoblotting. The molecular size indicated was 874 
determined using a molecular weight standard. (B) Quantification of (A). Values were 875 
normalized to the fraction with the highest amount of each respective protein. 876 
Figure 7. Loss of TIN2L phosphorylation inhibits progressive telomere elongation in 877 
telomerase positive HT1080 cells. (A) Representative telomere Southern blot analysis 878 
of telomere length in kilobasepairs (kb) over time in HT1080 cells overexpressing 879 
TIN2S, TIN2S-R282H, TIN2L, TIN2L-S396A, or TIN2L-S396E. HT1080 cells 880 
overexpressing the indicated TIN2 proteins were collected at various times following 881 
induction with lentivirus and blastocidin selection and analyzed by the terminal 882 
restriction fragment assay. (B) Quantification of (A) using densitometry analysis. Error 883 
bars indicate the SD of two separate terminal restriction fragment assays. (C) Western 884 
blot showing TIN2 expression levels in each cell line. Total cell protein lysates were 885 
prepared using 2X Laemmli buffer. 886 
Figure 8. Telomere lengths of TIN2L mutant HT1080 cell lines are indistinguishable 887 
from TIN2L wildtype lines. (A) XpYp STELA analysis of DNA isolated at the indicated 888 
numbers of days from the point of clonal line derivation. Mean lengths, SD, and 889 
standard error (SD) in kb are indicated. +veC, 293 cell line. (B) Individual telomere 890 
lengths in the designated lines at the designated days. 891 
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Figure 9. The telomere association of TRF1 and TRF2 is unaffected by loss of TIN2L 892 
function. Endogenous TRF1 and TRF2 were immunoprecipitated from lysates prepared 893 
from formaldehyde crosslinked cells. Association with telomeric DNA was assessed by 894 
(A) Southern blotting. IgG and Alu probes were included as controls for nonspecific 895 
association. (B) Average percent telomeric DNA in IP relative to input, +/- 1 SD (n=3). 896 









